David Allison Ph.D Overview
- Company
- IPI Legacy Liqui...
- Primary Position
-
Board Member
- Primary Industry
-
Healthcare
- Active Board Seats
-
7
- Med. Deal Size
-
- Med. Valuation
-
David Allison Ph.D General Information
Biography
Dr. David Allison serves as Board Member at IPI Legacy Liquidation. He serves as Managing Director at Westlake Village BioPartners. He serves as Board Member at Soteria Biotherapeutics and Borealis Biosciences. He also serves as Board Member at Recludix Pharma. He has served as a member of our Board of Directors since June 2019. He served as Board Member at Radionetics Oncology and Magnetic Insight. He served as Board Member at 5AM Ventures. He has served as a Partner at 5 AM Venture Management, LLC since July 2018, and was previously a Principal at 5 AM Venture Management, LLC since August 2016. He previously served as a Principal at Versant Ventures from April 2014 to August 2016. Prior to Versant Ventures, He worked at Split Rock Partners as a Principal from August 2009 to August 2014, and at PTV Healthcare Capital as a Senior Associate from 2006 to 2009. He currently serves on the boards of directors of various private companies and as a Director and Audit Committee Member at CinCor Pharma, Inc. (NASDAQ: CINC). He received a Ph.D. in Bioengineering from Rice University and a B.S.E in Biomedical Engineering from The University of Iowa.
Contact Information
Address
- 201 Elliott Avenue West
- Suite 260
- Seattle, WA 98119
- United States
David Allison Ph.D Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Westlake Village BioPartners | Investor | Managing Director | Westlake Village, CA | Venture Capital |
David Allison Ph.D Board Seats (7)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
3T Biosciences | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | South San Francisco, CA | |
Borealis Biosciences | Discovery Tools (Healthcare) | Privately Held (backing) | Venture Capital-Backed | Vancouver, Canada | |
IPI Legacy Liquidation | Drug Discovery | Privately Held (backing) | Formerly VC-backed | Seattle, WA | |
Neurogastrx | Therapeutic Devices | Privately Held (backing) | Venture Capital-Backed | Woburn, MA | |
Recludix Pharma | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | San Diego, CA |
David Allison Ph.D Lead Partner on Deals (13)
David Allison Ph.D has been the lead partner on 13 deals. Their latest deal was with Borealis Biosciences, a discovery tools (healthcare) company. The deal was made for on 27-Nov-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Borealis Biosciences | 27-Nov-2024 | Early Stage VC (Series A) | Completed | Discovery Tools (Healthcare) | Vancouver, Canada | |
Radionetics Oncology | 03-Jan-2024 | Completed | Drug Discovery | Menlo Park, CA | ||
Recludix Pharma | 15-Nov-2021 | Completed | Drug Discovery | San Diego, CA | ||
Magnetic Insight | 01-Oct-2021 | Completed | Diagnostic Equipment | Alameda, CA | ||
CinCor Pharma | 22-Sep-2021 | Completed | Drug Discovery | Waltham, MA | ||
Soteria Biotherapeutics | 17-May-2021 | Completed | Drug Discovery | San Mateo, CA | ||
CinCor Pharma | 14-May-2019 | Completed | Drug Discovery | Waltham, MA | ||
Magnetic Insight | 11-Dec-2018 | Completed | Diagnostic Equipment | Alameda, CA | ||
IPI Legacy Liquidation | 06-Dec-2018 | Later Stage VC (Series D) | Completed | Drug Discovery | Seattle, WA | |
Neurogastrx | 01-Aug-2018 | Later Stage VC (Series A) | Completed | Therapeutic Devices | Woburn, MA |
David Allison Ph.D Network (197)
Board Members (106)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Mette Agger | ScPharmaceuticals | Lundbeckfonden BioCapital | Burlington, MA | |
Zachary Hornby | Radionetics Oncology | Self | Menlo Park, CA | |
Magnetic Insight | Celesta Capital | Alameda, CA | ||
Magnetic Insight | ChinaEquity Group | Alameda, CA | ||
ScPharmaceuticals | Self | Burlington, MA |
Portfolio Executives (79)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Jerel Davis Ph.D | Borealis Biosciences | Chairman | 27-Nov-2024 | Vancouver, Canada |
Christian Hordo | Borealis Biosciences | Chief Executive Officer | 27-Nov-2024 | Vancouver, Canada |
Radionetics Oncology | Chief Executive Officer & Board Member | 03-Jan-2024 | Menlo Park, CA | |
Radionetics Oncology | Founding Member & Chief Research Officer | 03-Jan-2024 | Menlo Park, CA | |
Radionetics Oncology | Chief Operating Officer | 03-Jan-2024 | Menlo Park, CA |
Fund Team Members (12)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Beth Seidenberg MD | Westlake Village BioPartners | Westlake BioPartners Fund II | Westlake Village, CA |
Beth Seidenberg MD | Westlake Village BioPartners | Westlake BioPartners Fund I | Westlake Village, CA |
5AM Ventures | San Francisco, CA | ||
Westlake Village BioPartners | Westlake Village, CA | ||
5AM Ventures | San Francisco, CA |
David Allison Ph.D Affiliated Funds (6)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
5AM Opportunities II | 5AM Ventures | Venture Capital - Later Stage | Closed | 2021 | ||||
5AM Ventures VI | 5AM Ventures | Venture Capital - Early Stage | Closed | 2018 | ||||
Westlake BioPartners Fund II | Westlake Village BioPartners | Venture - General | Closed | 2022 | ||||
5AM Opportunities I | 5AM Ventures | Venture Capital - Later Stage | Closed | 2018 | ||||
5AM Ventures V | 5AM Ventures | Venture Capital - Early Stage | Closed | 2016 |
David Allison Ph.D FAQs
-
Who is David Allison Ph.D?
Dr. David Allison serves as Board Member at IPI Legacy Liquidation.
-
How much does David Allison Ph.D typically invest?
David Allison Ph.D's median deal size is
. -
What is David Allison Ph.D’s main position?
David Allison Ph.D’s primary position is Board Member.
-
How many active board seats does David Allison Ph.D hold?
David Allison Ph.D holds 7 board seats including 3T Biosciences, Borealis Biosciences, IPI Legacy Liquidation, Neurogastrx, and Recludix Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »